Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurodegeneration Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HSP90AB1/HSP90B drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HSP90AB1/HSP90B ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View HSP90AB1 Products |
| Gene Delivery | HSP90AB1/HSP90B Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View HSP90AB1 Products |
| Benchmark Ab | Anti-HSP90AB1/HSP90B Recombinant positive control. |
View HSP90AB1 Products |
| Validator | HSP90AB1/HSP90B siRNA Set For knockdown verification. |
View HSP90AB1 Products |
| Related Target A | HSP90AA1 Alpha isoform for selectivity counter-screening. |
View HSP90AA1 Products |
| Related Target B | CDC37 Co-chaperone interaction disruption assays. |
View CDC37 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform counter-screening (Alpha vs Beta) | Homolog panel proteins strictly verified by mass spec and sequence analysis |
| Co-chaperone interaction testing | High-purity recombinant proteins (>95%) for accurate SPR binding assays |
| Lack of Controls | Clinical Benchmark Antibodies included |
| False Positives | Validated siRNA included for specificity checks |
Live HSP90AB1/HSP90B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HSP90AB1/HSP90B therapeutics is evolving. Historically hampered by toxicity issues associated with first-generation pan-inhibitors, modern approaches are exploring novel allosteric modulators, PROTAC-mediated degradation, and optimized dosing strategies. As first-generation therapies navigate the clinic, the next wave of R&D is targeting refined patient stratification and combination therapies to overcome resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Pan-HSP90 Inhibitors | Taiho Pharmaceutical (e.g., Pimitespib) | GIST, Solid Tumors | Selectivity Assay (Need High-Purity Proteins) |
| PROTACs | Multiple Academic Institutions & Biotech | Oncology | Ternary Complex Validation (Need active ligase & target) |
| Small Molecules | Various | Neurodegeneration | Binding Assays (Need Native Conformation) |